Physician profile
Norvin Perez
NPI 1346235819
$448.23
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.34 · 2021: $21.15 · 2023: $207 · 2024: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $80.36 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $73.72 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $65.57 | 2023-2024 | |
| Abbvie INC. | $61.00 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $24.23 | 2023 | Austedo Xr |
| Medtronic, INC. | $24.20 | 2024 | Minimed 780g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.49 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.63 | 2023 | |
| Merck Sharp & Dohme LLC | $21.15 | 2021 | |
| Lilly USA, LLC | $19.80 | 2024 | Zepbound, Jardiance |
| Astellas Pharma US INC | $19.56 | 2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $14.52 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norvin Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.